J.L. Bainbridge & Co’s Antares Pharma, Inc. ATRS Stock Holding History

J.L. Bainbridge & Co’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,000	Closed	-$123K	–	91
2022 Q1	$123K	Hold	30,000	–	–	0.01%	87
2021 Q4	$107K	Hold	30,000	–	–	0.01%	88
2021 Q3	$109K	Hold	30,000	–	–	0.01%	93
2021 Q2	$131K	Hold	30,000	–	–	0.02%	90
2021 Q1	$123K	Hold	30,000	–	–	0.02%	88
2020 Q4	$120K	Hold	30,000	–	–	0.02%	83
2020 Q3	$81K	Hold	30,000	–	–	0.01%	78
2020 Q2	$82K	Hold	30,000	–	–	0.01%	68
2020 Q1	$71K	Hold	30,000	–	–	0.01%	70
2019 Q4	$141K	Hold	30,000	–	–	0.02%	84
2019 Q3	$100K	Hold	30,000	–	–	0.02%	77
2019 Q2	$99K	Hold	30,000	–	–	0.02%	72
2019 Q1	$92K	Hold	30,000	–	–	0.01%	65
2018 Q4	$82K	Hold	30,000	–	–	0.01%	68
2018 Q3	$101K	Buy	+30,000	New	+$92.7K	0.01%	72

Other funds holding ATRS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

J.L. Bainbridge & Co's ATRS Position: Q2 2022 in Review

J.L. Bainbridge & Co sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 30,000 shares — an estimated $123K sold.

J.L. Bainbridge & Co first reported a position in ATRS in Q3 2018 and held it in 15 quarters. The position peaked at $141K in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

J.L. Bainbridge & Co reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
J.L. Bainbridge & Co sold 30,000 Antares Pharma, Inc. shares in Q2 2022, an estimated $123K.
J.L. Bainbridge & Co first reported a position in Antares Pharma, Inc. in Q3 2018 and held it in 15 quarters.
J.L. Bainbridge & Co's Antares Pharma, Inc. position peaked at $141K in Q4 2019.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on J.L. Bainbridge & Co's 13F filing for Q2 2022, filed 4 Aug 2022.